USARx offers the following ways to purchase this medication. Choose the Best option for you!
Note: This document contains side effect information about isocarboxazid. Some of the dosage forms listed on this page may not apply to the brand name Marplan.In Summary
Common side effects of Marplan include: dizziness and headache. Other side effects include: suicidal ideation, suicidal tendencies, drowsiness, sleep disorder, tremor, nausea, and orthostatic hypotension. See below for a comprehensive list of adverse effects.For the Consumer
Applies to isocarboxazid: oral tablet
Oral route (Tablet)
Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients.
Along with its needed effects, isocarboxazid (the active ingredient contained in Marplan) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking isocarboxazid:
Incidence not known
Some side effects of isocarboxazid may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Incidence not known
For Healthcare Professionals
Applies to isocarboxazid: oral tabletCardiovascular
Common (1% to 10%): Orthostatic hypotension, palpitations
Frequency not reported: Disturbances in cardiac rhythm, peripheral edema
Orthostatic hypotension, disturbances in cardiac rhythm, and/or peripheral edema may be controlled by reducing the dose.Nervous system
Dizziness and/or drowsiness may be controlled by reducing the dose.
Very common (10% or more): Dizziness (up to 29%), headache (up to 15%)
Common (1% to 10%): Drowsy/drowsiness, forgetful, hyperactive, lethargy, myoclonic jerks, paresthesia, sedation, syncope, tremor
Frequency not reported: Hyperreflexia, mild headache, overactivity, peripheral neuritis
Postmarketing reports: Akathisia, ataxia, coma, neuritisGastrointestinal
Common (1% to 10%): Constipation, diarrhea, dry mouth, nausea
Frequency not reported: Vomiting
Postmarketing reports: Black tongue
Constipation, dry mouth, nausea, and/or vomiting may be controlled by reducing the dose.Ocular
Frequency not reported: Blurred vision
Postmarketing reports: Toxic amblyopia
Blurred vision may be controlled by reducing the dose.
Toxic amblyopia was reported in a patient with schizophrenia who received this drug for approximately 1 year; however, no causal relationship to this drug was established.Musculoskeletal
Frequency not reported: Muscle tremorGenitourinary
Common (1% to 10%): Impotence, urinary frequency, urinary hesitancy
Frequency not reported: Difficulty in micturition, impairment of erection and ejaculation
Postmarketing reports: Dysuria, incontinence, sexual disturbances, urinary retentionGeneral
The most common adverse events were dizziness, headache, nausea, and dry mouth.Endocrine
Postmarketing reports: Impaired water secretion compatible with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)Dermatologic
Common (1% to 10%): Sweating
Frequency not reported: Skin rashes
Postmarketing reports: Photosensitivity, spider telangiectasesPsychiatric
Insomnia may be controlled by reducing the dose.
Hallucinations have been reported with high doses, but have disappeared with dose reduction or discontinuation of therapy.
Common (1% to 10%): Anxiety, insomnia, sleep disturbance
Frequency not reported: Agitation, behavioral changes, confusion, suicidal behavior, suicidal ideation
Postmarketing reports: Euphoria, hallucinationsOther
Common (1% to 10%): Chills, heavy feeling
Frequency not reported: Fatigue, weakness
Fatigue and/or weakness may be controlled by reducing the dose.Hematologic
Rare (less than 0.1%): Blood dyscrasias, granulocytopenia, purpura
Postmarketing reports: Hematologic changesMetabolic
Frequency not reported: Increased appetite, weight gain
December 16, 2020
March 1, 2021
February 15, 2021
March 1, 2021
February 1, 2021
January 31, 2021